Director's Career Symposium

Join us for the 1st annual Integrated Training in Cancer Model Systems Director’s Career Symposium featuring career focused talks from invited speakers representing three different career paths: Pharmaceutical Industry, and Science Writing.

  • Director's Career Symposium
  • 2017-05-15T12:30:00-04:00
  • 2017-05-15T16:30:00-04:00
  • Join us for the 1st annual Integrated Training in Cancer Model Systems Director’s Career Symposium featuring career focused talks from invited speakers representing three different career paths: Pharmaceutical Industry, and Science Writing.
When May 15, 2017 from 12:30 PM to 04:30 PM (EST / UTC-400)
Where Pagano Conference Room - LCCC 00-002
Contact Name
Add event to calendar iCal

In addition to a full afternoon of career talks, we are offering concurrent breakout sessions with each invited speaker for interested postdocs who are interested in learning more about a particular career path.  If you are interested in a more in-depth discussion with one of the speakers please pre-register for that breakout session.  Coffee and snacks will be served at the breakout sessions.

Register for Breakout Sessions

Agenda:

12:30 pmPizza served for postdocs/attendees
1:00 - 1:30 pm

Lesley Griner, PhD, Investigator III
Molecular Pharmacology, Oncology Drug Discovery Research
Novartis Institutes for BioMedical Research

1:35 - 2:05 pm

Ana Batista, PhD, Editor, Trends In Cancer (Cell Press)

2:10 - 2:40 pm Kevin Healy, PhD, RAC, Senior Director, Global Regulatory Affairs
Roivant Sciences, Inc.
2:45 - 3:15 pm Questions/Discussion
3:30 - 4:30 pm

Breakout Sessions with speakers, registration required:

Pagano Conference Room: Lesley Griner, PhD
LCCC 22-001: Kevin Healy, PhD 
LCCC 32-001: Ana Batista, PhD

 

Lesley Griner, PhD, Investigator III, Molecular Pharmacology, Oncology Drug Discovery Research, Novartis Institutes for BioMedical Research

Lesley's role at NIBR is to drive projects through the development of novel high throughput cellular assays for SAR compound expansion and hit-to-lead validation.  Lesley is engaged in directing project teams toward candidate selection by managing cellular assays, biochemistry and medicinal chemistry optimization of key portfolio projects, including targets related to small molecules, immuno-oncology, targeted degraders, antibody-drug conjugates, bispecific antibodies and biologics. She serves as a core project team member for cellular assay development including alignment of PK/PD relationships and biomarker selection in conjunction with patient stratification using molecular diagnostics/cell free DNA sequencing. As projects progress, her role includes preparation of in house Research Document Systems (RDS) leading to submissions of Investigational New Drug Applications (IND) to the FDA and design of First Patient First Visit (FPFV) Phase I Clinical Trials for lead IND candidates. Prior to her role at NIBR, Lesley was a Research Scientist in the Biomolecular Screening and Profiling/Probe Development group at the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH). She joined NCATS in December 2010 after completing her postdoctoral research training at NCI-Frederick working on epigenetics and cancer stem cells. Lesley completed her Ph.D. in Molecular and Cellular Biology from the University of Massachusetts at Amherst and earned a Bachelor’s in Biology at Clark University in Worcester, MA. Lesley currently lives in Ayer, MA with her husband Nick and two cats, Bailey and Schwartz. 

Ana Batista, PhD, Editor, Trends In Cancer (Cell Press)

Ana’s role at Trends in Cancer is to develop the journal strategy, commission expert reviews and commentary pieces in cancer, and oversee the editorial process. As part of growing the journal outreach, Ana is also involved in the planning of conferences, marketing and sales events, and also manages graphic content. Ana is a graduate of the University of Coimbra, Portugal. She completed research for her MSc at UTSW Medical Center and PhD at the Dana-Farber Cancer Institute and IU Simon Cancer Center, where she studied stromal-tumor crosstalk in pediatric blood cancers. She completed her postdoctoral research with Dr. Rakesh K. Jain at MGH-Harvard, where she worked on critical issues in brain cancers, tumor microenvironment and metastasis.

Kevin Healy, PhD, RAC, Senior Director, Global Regulatory Affairs, Roivant Sciences, Inc.

 As a Senior Director of Global Regulatory Affairs at Roivant Sciences, Kevin is responsible for developing and executing efficient global drug development strategies. Roivant is a global healthcare company focused on realizing the full value of promising biomedical research, and has a diverse pipeline in neurology, oncology, endocrinology, dermatology, urology, and rare diseases. Prior to joining Roivant, Kevin contributed to and led successful drug development programs at Mallinckrodt Pharmaceuticals, Gilead Sciences, and SRA, a contract research organization. Kevin obtained his PhD in Biochemistry from the University of Wisconsin-Madison and completed his postdoctoral research under the guidance of Dr. Channing Der at the University of North Carolina Lineberger Comprehensive Cancer Center.